Santhera Pharmaceuticals Holding AG (SANN.SW) SIX
Currency In CHF
- General
- Statistics
- Historical Data
- Profile
- Financials
Santhera Pharmaceuticals Holding AG
Address
Hohenrainstrasse 24
Pratteln, 4133
Switzerland
Phone
41 61 906 89 50
Website
Sector
Healthcare
Industry
Biotechnology
Employees
78
First IPO Date
November 03, 2006
Key Executives
| Name | Title | Pay | Year Born |
| Dario Eklund | Chief Executive Officer | 1.23M | 1968 |
| Thomas Meier | Founder & Chairman | 200,000 | 1962 |
| Andreas Missy | Executive Vice President of Corporate Planning & Business Development | 0 | N/A |
| Geert Jan van Daal | Chief Commercial Officer | 0 | 1960 |
| Oliver Kronenberg | Chief Legal Officer & Corporate Secretary | 0 | 1968 |
| Shabir Hasham | Chief Medical Officer | 0 | 1970 |
| Marc Schrader | Chief Technology Officer | 0 | 1971 |
| Neville Kodkani | Head of Global Marketing & Partner Management | 0 | N/A |
| Oliver Strub | Head of Compliance | 0 | 1963 |
| Catherine Ann Isted | Chief Financial Officer | 0 | 1975 |
| Sarah Holmes-Klotz | Global Head of People & Culture | 0 | N/A |
Description
Santhera Pharmaceuticals Holding AG is a specialized biopharmaceutical firm dedicated to advancing and distributing therapeutic solutions for rare neurological and respiratory conditions characterized by significant patient need across the globe, including the European Union. A cornerstone of its development efforts is vamorolone, currently undergoing clinical trials as a potential treatment for Duchenne muscular dystrophy (DMD). The company's clinical pipeline is further enriched by lonodelestat (also known as POL6014), aimed at addressing cystic fibrosis and various other neutrophilic pulmonary ailments, alongside omigapil, which targets congenital muscular dystrophies. Beyond its pipeline, Santhera also licenses the distribution rights for its approved product, Raxone (idebenone), for the management of Leber's hereditary optic neuropathy, in regions excluding North America and France. Established in 2004, Santhera Pharmaceuticals Holding AG maintains its corporate headquarters in Pratteln, Switzerland.
